NovImmune SA Appoints Adrian Mills As Chief Business Officer And Member Of The Executive Committee
Geneva, Switzerland, 10 September 2014 – Novimmune announces today that it has appointed Adrian Mills as the Company's Chief Business Officer and member of the Executive Committee (EC), with immediate effect. Adrian will be leading Novimmune’s commercial development activities as well as Business Development. David Slack, Head of Corporate and Business Development, is leaving Novimmune to focus on opportunities outside the Company.
Jack Barbut, Chief Executive Officer of Novimmune, commented: "I am pleased to welcome Adrian as Chief Business Officer. He brings over 20 years of experience as a pharmaceutical executive with a particular focus on the commercialization of orphan drugs."
Adrian Mills is a British citizen joining Novimmune from GlaxoSmithKline plc (GSK), where he held various strategic and operational positions from 2000 until 2013 in Europe and SE Asia. Most recently Adrian was European Commercial Director for Rare and Critical Diseases. Prior to GSK, Adrian worked in management consulting and investment banking in the life sciences sector. He holds an MBA from the London Business School and an MA (Hons) Engineering from Queens’ College, Cambridge.
Thanking David Slack for his contribution, Jack Barbut said: "David has made a valuable contribution to our business development efforts and in general at the Executive Team level. We wish him every success for his future”.
For further information please contact:
Tel: +41 22 839 71 41
Jack Barbut CEO
Andrew Oakley CFO
Tel: +44 020 3727 1000
Novimmune SA is a leading drug discovery and development company focused on the creation of antibody-based drugs to benefit patients with inflammatory, auto-immune and other disorders. To date, Novimmune has advanced seven drug candidates to treat a range of conditions. The company has a diverse clinical pipeline that includes NI-0501, NI-0101 and NI-1401.
NI-0501 is an anti-interferon g monoclonal antibody that is currently in a Phase II study as a treatment for the orphan disease Hemophagocytic Lymphohistiocytosis, a potentially lethal inflammatory syndrome.
NI-0101 is a first-in-class anti-TLR4 monoclonal antibody. TLR4 is an important receptor on the pathway leading to the activation of the innate immune system. As such, it has been implicated as a target in drug discovery for a range of conditions including rheumatoid arthritis, lung disease, diabetes, and kidney disease. NI-0101 has recently successfully completed a Phase I clinical program and Novimmune intends to initially progress it as potentially the first personalized medicine for rheumatoid arthritis.
NI-1401 is a differentiated anti IL-17 monoclonal antibody that binds the 3 forms of IL-17 A and F. It was licensed to Genentech, prior to Phase I initiation, in 2010. Genentech has assumed all responsibility and costs for development and is expected to announce initiation of a Phase II clinical program in early 2015.
Novimmune has also developed a proprietary bi-specific antibody platform to help further expand its pipeline.
In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for orphan drug applications.
Help employers find you! Check out all the jobs and post your resume.